Source:http://linkedlifedata.com/resource/pubmed/id/11071630
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2000-11-27
|
| pubmed:abstractText |
Recent observations have underscored the biologic relevance of intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow angiogenesis has been demonstrated in a variety of hematologic disorders, including multiple myeloma. The extent and prognostic significance of bone marrow angiogenesis in 114 patients with myelofibrosis with myeloid metaplasia (MMM) was investigated. A control group of 44 patients without bone marrow disease, 15 patients with polycythemia vera, and 17 patients with essential thrombocythemia was also studied. Bone marrow microvessel density was assessed by a semiquantitative method, visual microvessel grading, and 2 separate quantitative methods, visual count and computerized image analysis. Angiogenesis estimation by all 3 methods was highly comparable. On visual microvessel grading, a grade 3 or 4 increase in bone marrow angiogenesis was demonstrated in 70% of patients with MMM, 33% of patients with polycythemia vera, 12% of patients with essential thrombocythemia, and 0% of normal controls. In a multivariate analysis, increased angiogenesis in MMM correlated significantly with increased spleen size and was found to be a significant and independent risk factor for overall survival. Increases in marrow angiogenesis correlated with hypercellularity and megakaryocyte clumping. In contrast, these 2 features were inversely proportional to reticulin fibrosis, whereas increases in marrow angiogenesis were independent of reticulin fibrosis. These preliminary findings suggest that neo-angiogenesis is an integral component of the bone marrow stromal reaction in MMM and may provide useful prognostic information and a rationale for the therapeutic investigation of anti-angiogenic agents.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
96
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3374-80
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:11071630-Adult,
pubmed-meshheading:11071630-Aged,
pubmed-meshheading:11071630-Aged, 80 and over,
pubmed-meshheading:11071630-Bone Marrow,
pubmed-meshheading:11071630-Cohort Studies,
pubmed-meshheading:11071630-Female,
pubmed-meshheading:11071630-Histocytochemistry,
pubmed-meshheading:11071630-Humans,
pubmed-meshheading:11071630-Male,
pubmed-meshheading:11071630-Microcirculation,
pubmed-meshheading:11071630-Middle Aged,
pubmed-meshheading:11071630-Multivariate Analysis,
pubmed-meshheading:11071630-Neovascularization, Pathologic,
pubmed-meshheading:11071630-Polycythemia Vera,
pubmed-meshheading:11071630-Primary Myelofibrosis,
pubmed-meshheading:11071630-Prognosis,
pubmed-meshheading:11071630-Prospective Studies,
pubmed-meshheading:11071630-Risk Factors,
pubmed-meshheading:11071630-Survival Rate,
pubmed-meshheading:11071630-Thrombocythemia, Essential
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia.
|
| pubmed:affiliation |
Division of Hematology and Internal Medicine, the Division of Hematopathology, and the Cancer Center Statistics Unit, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|